WO2001082871A3 - Method of using zinc isotope for therapy and diagnosis of colon cancer - Google Patents
Method of using zinc isotope for therapy and diagnosis of colon cancer Download PDFInfo
- Publication number
- WO2001082871A3 WO2001082871A3 PCT/US2001/014664 US0114664W WO0182871A3 WO 2001082871 A3 WO2001082871 A3 WO 2001082871A3 US 0114664 W US0114664 W US 0114664W WO 0182871 A3 WO0182871 A3 WO 0182871A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diagnosis
- colon cancer
- therapy
- zinc isotope
- isotope
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0476—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention relates generally to treatment and diagnosis of cancer, and more specifically to treatment and diagnosis of colon cancer employing a zinc isotope or a combination of a zinc isotope and a phosphate binder.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56691900A | 2000-05-04 | 2000-05-04 | |
US09/566,919 | 2000-05-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001082871A2 WO2001082871A2 (en) | 2001-11-08 |
WO2001082871A3 true WO2001082871A3 (en) | 2002-02-28 |
Family
ID=24264957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/014664 WO2001082871A2 (en) | 2000-05-04 | 2001-05-04 | Method of using zinc isotope for therapy and diagnosis of colon cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2001082871A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8986669B2 (en) | 2005-09-02 | 2015-03-24 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1830832A1 (en) * | 2004-12-30 | 2007-09-12 | Genzyme Corporation | Zinc-containing treatments for hyperphosphatemia |
US10226484B2 (en) | 2014-12-01 | 2019-03-12 | Peter Y Novak | Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof |
JP2019535839A (en) | 2016-11-29 | 2019-12-12 | ピュアテック ヘルス エルエルシー | Exosomes for the delivery of therapeutic agents |
US10183041B2 (en) | 2017-04-12 | 2019-01-22 | Vector Vitale Ip Llc | Antibacterial composition and its use in treating bacterial infections |
US11484610B2 (en) | 2019-11-22 | 2022-11-01 | Vector Vitale Ip Llc | Method of treating melanoma |
US10933091B1 (en) | 2019-12-20 | 2021-03-02 | Vector Vitale Ip Llc | Composition and method for the treatment of type I diabetes |
US10799530B1 (en) | 2019-12-20 | 2020-10-13 | Vector Vitale Ip Llc | Composition and method for the prevention and treatment of obesity |
US11596650B2 (en) | 2019-12-20 | 2023-03-07 | Vector Vitale Ip Llc | Composition and method for the treatment of type 2 diabetes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4758421A (en) * | 1985-03-15 | 1988-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | Bleomycin conjugates and method |
US4863713A (en) * | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
-
2001
- 2001-05-04 WO PCT/US2001/014664 patent/WO2001082871A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4758421A (en) * | 1985-03-15 | 1988-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | Bleomycin conjugates and method |
US4863713A (en) * | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8986669B2 (en) | 2005-09-02 | 2015-03-24 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
Also Published As
Publication number | Publication date |
---|---|
WO2001082871A2 (en) | 2001-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001282717A1 (en) | Cancer treatment by combination therapy | |
AU2001279707A1 (en) | Diagnosis of behavioural disorders, neurological disorders and cancer | |
AU2002322280A1 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
WO2004028454A3 (en) | 1, 3, 5-triazines for treatment of viral diseases | |
AU2002251841A1 (en) | Compositions and methods for the therapy and diagnosis of pancreatic cancer | |
WO2003059251A3 (en) | Antibody targeting compounds | |
AU2001268259A1 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
AU2002350235A1 (en) | Combination bacteriolytic therapy for the treatment of tumors | |
AU2001269766A1 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
AU2003300368A8 (en) | Methods and compositions for the diagnosis, prognosis, and treatment of cancer | |
MXPA03003632A (en) | Method for treatment of tumors using combination therapy. | |
AU2001280982A1 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
WO2000018439A3 (en) | Use of neoangiogenesis markers for diagnosing and treating tumours by therapy | |
WO2002077172A3 (en) | Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors | |
AU2002226030A1 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
WO2001082871A3 (en) | Method of using zinc isotope for therapy and diagnosis of colon cancer | |
WO2004033666A3 (en) | Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases | |
HK1041827A1 (en) | Compounds for the treatment of estrogen-defendent illnesses and methods for making and using the dame. | |
WO2004073615A3 (en) | Deazaflavin compounds and methods of use thereof | |
AU6425800A (en) | Agents for the diagnosis, prognosis and treatment of malignant diseases | |
MXPA03007036A (en) | Method of cancer therapy. | |
AU2596901A (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
WO2003073818A3 (en) | Proteomic analysis of tumors for development of consultative report of therapeutic options | |
AP2004003070A0 (en) | The method of treating cancer. | |
AU2001290518A1 (en) | Compositions and methods for the therapy and diagnosis of colon cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CN JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CN JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |